<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634812</url>
  </required_header>
  <id_info>
    <org_study_id>KBP5074-1-007</org_study_id>
    <nct_id>NCT04634812</nct_id>
  </id_info>
  <brief_title>Mass Balance Study of KBP-5074 in Healthy Male Subjects</brief_title>
  <official_title>A Phase 1, Open-label, Study of the Absorption, Metabolism, and Excretion of [14C]-KBP-5074 Following a Single Oral Dose in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KBP Biosciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Covance</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KBP Biosciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, nonrandomized, single-dose mass balance and metabolite&#xD;
      identification study in healthy male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 3, 2020</start_date>
  <completion_date type="Actual">December 23, 2020</completion_date>
  <primary_completion_date type="Actual">December 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mass Balance of KBP-5074</measure>
    <time_frame>up to 240 hours postdose</time_frame>
    <description>Percentage of total radioactivity recovered in urine and feces following a single dose [14C]-KBP-5074</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Area under the concentration-time curve from time 0 to infinity (AUC0-∞)</measure>
    <time_frame>up to 216 hours postdose</time_frame>
    <description>Area under the concentration-time curve from time 0 to infinity (AUC0-∞) - Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast)</measure>
    <time_frame>up to 216 hours postdose</time_frame>
    <description>Area under the plasma concentration time curve from time zero to time of last quantifiable concentration (AUC0-tlast) - Plasma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic Parameter: Time of the maximum observed concentration (Cmax)</measure>
    <time_frame>up to 216 hours postdose</time_frame>
    <description>Time of the maximum observed concentration (Cmax) - Plasma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metabolite radioprofiling and identification in plasma, urine and feces</measure>
    <time_frame>up to 240 hours postdose</time_frame>
    <description>Select plasma, urine, and fecal samples will be processed and subject to metabolite analysis by LC/MS &amp; LC/MS/MS using high-resolution mass spectrometry.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>[14C]-KBP-5074</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KBP-5074</intervention_name>
    <description>a single oral dose of [14C]-KBP-5074</description>
    <arm_group_label>[14C]-KBP-5074</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males, of any race, between 18 and 55 years of age, inclusive, at screening.&#xD;
&#xD;
          2. Body mass index between 18.0 and 32.0 kg/m2, inclusive, at screening.&#xD;
&#xD;
          3. In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination (assessed only at check-in), 12-lead ECG, vital sign&#xD;
             measurements, and clinical laboratory evaluations (congenital nonhemolytic&#xD;
             hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct&#xD;
             bilirubin] is not acceptable) at screening and check-in as assessed by the&#xD;
             investigator (or designee).&#xD;
&#xD;
          4. History of a minimum of 1 bowel movement per day.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, hepatic, renal, hematological, pulmonary, cardiovascular,&#xD;
             gastrointestinal, neurological, respiratory, endocrine, psychiatric, or other&#xD;
             disorder, as determined by the investigator (or designee).&#xD;
&#xD;
          2. History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs (uncomplicated appendectomy&#xD;
             and hernia repair will be allowed; cholecystectomy will not be allowed).&#xD;
&#xD;
          3. Positive urine drug screen, including cotinine, at screening; positive alcohol test&#xD;
             result or positive urine drug screen, including cotinine, at check-in.&#xD;
&#xD;
          4. Use of any drugs or substances known to be strong or moderate inhibitors or inducers&#xD;
             of cytochrome P450 (CYP)3A4 or P-glycoprotein substrates within 30 days prior to study&#xD;
             drug administration. Medications will be reviewed by the medical monitor to determine&#xD;
             acceptability for the study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James McCabe</last_name>
    <role>Study Director</role>
    <affiliation>KBP Biosciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>November 12, 2020</study_first_submitted>
  <study_first_submitted_qc>November 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Male Subjects</keyword>
  <keyword>KBP-5074</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

